Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation H Khoury, K Trinkaus, M.J Zhang, D Adkins,

Slides:

Advertisements

Similar presentations

Stephanie J. Lee, Loretta A. Williams

Advertisements

Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.

Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated.

Tumor Necrosis Factor-α Gene Polymorphisms Are Associated with Severity of Acute Graft-Versus-Host Disease Following Matched Unrelated Donor Bone Marrow.

Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell.

Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized.

Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations Yachiyo.

KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched.

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Therapy of Sclerodermatous Chronic Graft-Versus-Host Disease with Mammalian Target of Rapamycin Inhibitors Zuzana Jedlickova, Irina Burlakova, Gesine.

Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8+ T-cell count on day +14 as a predictor.

Daniela Ion, Kristen Stevenson, Sook-Bin Woo, Vincent T

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

A First-in-Disease Trial of in Vivo Costimulation Blockade for GVHD Prevention: The Addition of Abatacept to Standard GVHD Prophylaxis Controls Early.

Study Design of an Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients Years of Age with Secondary Acute.

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

ATG Prevents Severe Acute Graft-versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation Joseph Pidala, Marcie Tomblyn, Taiga.

Stephanie J. Lee, Loretta A. Williams

Re: Twenty-Year Follow-Up in Patients with Aplastic Anemia Given Marrow Grafts from HLA-Identical Siblings and Randomized to Receive Methotrexate/Cyclosporine.

Efficacy and Safety of Ex Vivo Cultured Adult Human Mesenchymal Stem Cells (Prochymal™) in Pediatric Patients with Severe Refractory Acute Graft-Versus-Host.

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source Sharat Damodar,

Recent Decrease in Acute Graft-versus-Host Disease in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants Stella M. Davies, Dan.

Graft Transit Time Has No Effect on Outcome of Unrelated Donor Hematopoietic Cell Transplants Performed in Australia and New Zealand: A Study from the.

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Role of the Mycobiome in Human Acute Graft-versus-Host Disease

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study

Dynamic Detection of Anti–Human Leukocyte Antigen (HLA) Antibodies but not HLA-DP Loci Mismatches Can Predict Acute Graft-versus-Host Disease and Overall.

Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation.

Sequential Intensified Conditioning and Tapering of Prophylactic Immunosuppressants for Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell.

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review

Paul J. Martin, Terry Furlong, Scott D. Rowley, Steven A

Reconstitution of Natural Killer Cell Receptor Repertoires after Unmanipulated HLA- Mismatched/Haploidentical Blood and Marrow Transplantation: Analyses.

Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation Has Unique Features and an Association with Engrafting Unit-to-Recipient HLA Match

Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell– Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous.

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.

Recipient PTPN22 −1123 C/C Genotype Predicts Acute Graft-versus-Host Disease after HLA Fully Matched Unrelated Bone Marrow Transplantation for Hematologic.

A Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease Daniel R. Couriel, Rima Saliba, Marcos.

Possible Association between Obesity and Posttransplantation Complications Including Infectious Diseases and Acute Graft-versus-Host Disease Shigeo Fuji,

Myeloablative Transplantation using either Cord Blood or Bone Marrow leads to Immune Recovery, High Long-Term Donor Chimerism and Excellent Survival in.

Mohammad Alhyari, M. D. , Aymen Bukannan, M. D. , Kimberly Brown, M. D

Equivalent Survival for Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia John Moore, Ian Nivison-Smith,

Allogeneic Transplantation for Adult Acute Leukemia in First and Second Remission with a Novel Regimen Incorporating Daily Intravenous Busulfan, Fludarabine,

Diarrhea during the Conditioning Regimen Is Correlated with the Occurrence of Severe Acute Graft-versus-Host Disease through Systemic Release of Inflammatory.

Double Umbilical Cord Blood Transplantation after Novel Myeloablative Conditioning Using a Regimen of Fludarabine, Busulfan, and Total Lymphoid Irradiation

Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft- versus-Host Disease: A Scoping Review of the Evidence Mina Rizk, Madeline.

Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.

High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic.

Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched.

HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category Ann Woolfrey, Stephanie J.

A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell.

Status of Donor-Recipient HLA Class I Ligands and Not the KIR Genotype Is Predictive for the Outcome of Unrelated Hematopoietic Stem Cell Transplantation.

Biology of Blood and Marrow Transplantation

Calcinuerin-Inhibitor (CI) Free Graft-Versus-Host Disease (GvHD) Prophylaxis: Its Effects on Magnesium, Renal Function, and the Cost of Care Marlee Muilenburg,

Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall.

Thymoglobulin® Exposure Is Influencing CD4+ Immune Reconstitution As a Predictor for Improved Overall Survival in Pediatric Haematopoietic Cell Transplantation:

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant.

Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation Abraham S. Kanate, Parameswaran.

Twenty-Year Follow-Up of a Controlled Trial Comparing a Combination of Methotrexate Plus Cyclosporine with Cyclosporine Alone for Prophylaxis of Graft-versus-Host.

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Myeloablative Regimens Including Pretransplant Antithymocyte Globulin Have Lower.

Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study Moshe Yeshurun,

Mary Eapen Biology of Blood and Marrow Transplantation

Infliximab for Managing Steroid-Refractory Acute Graft-versus-Host Disease Joseph Pidala, Jongphil Kim, Teresa Field, Ali McBride, Mohamed Kharfan-Dabaja,

Presentation transcript:

Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation H Khoury, K Trinkaus, M.J Zhang, D Adkins, R Brown, R Vij, L.T Goodnough, M.K Ma, H.L McLeod, S Shenoy, M Horowitz, J.F DiPersio Biology of Blood and Marrow Transplantation Volume 9, Issue 11, Pages 714-721 (November 2003) DOI: 10.1016/j.bbmt.2003.08.006

Figure 1 Correlation between HCQ serum levels and development of various grades of acute GVHD (aGVHD). There was no difference in HCQ levels that would predict severe (grades III and IV) acute GVHD (Kruskal-Wallis test; P = .35) Biology of Blood and Marrow Transplantation 2003 9, 714-721DOI: (10.1016/j.bbmt.2003.08.006)

Figure 2 Kaplan-Meier survival estimate for all URD recipients enrolled on the HCQ prophylactic trial (n = 52). Biology of Blood and Marrow Transplantation 2003 9, 714-721DOI: (10.1016/j.bbmt.2003.08.006)

Figure 3 Overall acute GVHD and grade III and IV acute GVHD (AGVHD)-free survival for forty-two 6-antigen-matched URD recipients enrolled on the HCQ prophylactic trial and IBMTR controls. Biology of Blood and Marrow Transplantation 2003 9, 714-721DOI: (10.1016/j.bbmt.2003.08.006)